PR98581

MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire=KYODO JBN/ --

-- Seasoned Executive has Successful Track Record Working with Global Investors

to Raise Billions of Dollars

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, today announced it has

appointed Richard "Ric" Peterson as chief financial officer.

Photo -

https://mma.prnewswire.com/media/1935041/Turn_Biotechnologies_Ric_Peterson.jpg

Logo - https://mma.prnewswire.com/media/1935529/TURN_LOGO_HI_RES_Logo.jpg

Mr. Peterson, who has served as CFO of numerous public and private biotech and

pharmaceutical companies, has deep experience with private financing, public

offerings, and complex global transactions. He will oversee all financial

functions and fundraising efforts as Turn Bio prepares to launch its clinical

programs.

"Ric's background with biotech companies in various stages of development and

his experience as a financial and business leader will be great assets as Turn

Bio moves into the next phases of growth," said company CEO Anja Krammer. "As

Turn Bio progresses toward the clinic, Ric will enhance our team's expertise

and help communicate our unique vision for treating the diseases of aging

within the investment community."

During his 25 years of serving as a chief financial officer, Peterson has led

traditional fundraising efforts for pre-clinical, clinical and commercial

companies, managed initial public offerings and overseen corporate purchases

and sales. He has completed more than 40 transactions representing billions of

dollars.

"I am excited to join the team at Turn Bio at this important stage, when the

company's potential for growth and value creation is exceptional," said

Peterson. "The talented team of executives and cell rejuvenation pioneers has

brought Turn Bio successfully to this point, achieved breakthroughs in

epigenetic reprogramming and developed a game-changing delivery system that

overcomes the leading obstacle to cell therapies.  I look forward to helping

steer the next stage of our growth."

Peterson has worked with several clinical stage biopharmaceutical companies,

including Clarus Therapeutics, Sienna Biopharmaceuticals, Dermavant Sciences

Inc., and Novan Inc. He was also CFO of Medicis Pharmaceutical Corporation, a

commercial pharmaceutical company. Under Peterson's guidance, Novan and Sienna

completed successful IPOs. At Medicis, he helped lead the company's growth,

which resulted in its acquisition for $2.6 billion by Valeant Pharmaceuticals

International.

Peterson serves as a director at Universal Insurance Holdings, where he chairs

the Board's Audit Committee.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level and developing transformative drug delivery systems. The

company's proprietary mRNA platform technology, ERA(TM), restores optimal gene

expression by combatting the effects of aging in the epigenome. This restores

cells' ability to prevent or treat disease and heal or regenerate tissue. It

will help to fight incurable chronic diseases. Its eTurna(TM) Delivery Platform

uses unique formulations to precisely deliver cargo to specific organs,

tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting

indications in dermatology and immunology, and developing therapies for

ophthalmology, osteo-arthritis, and the muscular system. For more information,

see www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or (312) 543-9026

SOURCE: Turn Biotechnologies, Inc.